On July 29, 2026, the Health Care Select Sector SPDR ETF (ticker: XLV) established key technical pivot points that investors should watch closely. The DeMark technique identified a Pivot High at $169.28 and a Pivot Low at $166.50, signaling potential directional moves in the healthcare sector ETF's price action.
- XLV offers a dividend yield of 1.51% with a payout ratio of 37%, supported by a healthy 3-year dividend growth rate of 8.1%, indicating a sustainable and moderately growing income stream. The GF Value™ suggests the ETF is slightly overvalued by 0.8% compared to its intrinsic value of $165.89.
- The ETF’s GF Score™ stands at a robust 82 out of 100, reflecting strong overall fundamentals, particularly in profitability and growth metrics.
- From a financial perspective, XLV enjoys solid backing from institutional gurus, with 8 premium gurus holding the ETF and a net positive trend of 5 additions versus 3 trims in recent quarters, underscoring confidence among top investment managers.
What's Behind the News?
The recent identification of pivot points for XLV using the DeMark technique highlights critical price levels that traders and investors can use to anticipate potential market moves. A break above the Pivot High at $169.28 would be a bullish signal, suggesting upward momentum, while a drop below the Pivot Low at $166.50 would indicate bearish pressure. Such technical signals are especially relevant for an ETF like XLV, which tracks the healthcare sector and is often used as a barometer for healthcare industry performance.
XLV, formally known as the State Street Health Care Select Sector SPDR ETF, is a major player on the ARCA exchange with a market capitalization of $43.77 billion. While it does not generate revenue or earnings itself, as an ETF it aggregates the performance of healthcare-related equities, providing investors diversified exposure to the sector. Its relatively low beta of 0.47 suggests less volatility compared to the overall market, making it attractive for risk-conscious investors.
Is XLV's Dividend Safe and Attractive?
XLV currently yields 1.51%, a modest but meaningful income stream for dividend investors. The payout ratio of 37% indicates that the ETF’s underlying holdings distribute dividends at a sustainable level relative to their earnings, leaving ample room for continued dividend growth or stability even in less favorable market conditions. Supporting this, the ETF’s dividend growth rate over the past three years has been a healthy 8.1%, signaling a consistent upward trajectory in income potential.
From a valuation standpoint, the GF Value™ of $165.89 compared to the current price of $167.26 suggests XLV is trading approximately 0.8% above its intrinsic value estimate. While this represents a slight overvaluation, it is marginal and should not be a significant deterrent for dividend-focused investors seeking steady income. For more on GF Value™, see GF Value™.
What Does XLV's GF Score™ Tell Us?
The GF Score™ is a composite metric that evaluates a stock or ETF’s overall quality by analyzing financial strength, profitability, growth, valuation, and momentum. XLV’s score of 82/100 indicates a strong fundamental profile, particularly in profitability and growth, while momentum is comparatively weaker.
| Metric | Rating (out of 10) |
|---|---|
| GF Score™ | 82 |
| Financial Strength | 6 |
| Profitability | 8 |
| Growth | 8 |
| Valuation | 7 |
| Momentum | 4 |
XLV’s strongest attributes lie in its profitability and growth ranks, both scoring 8 out of 10, reflecting healthy margins and solid earnings and EBITDA growth rates over recent years. Financial strength is moderate at 6, indicating a stable balance sheet, while valuation at 7 suggests the ETF is reasonably priced relative to fundamentals. Momentum is the weakest area at 4, implying recent price trends have been less robust. For further details, visit the XLV stock page.
What Are Gurus and Insiders Doing with XLV?
One of the most compelling signals for XLV comes from premium guru activity tracked by GuruFocus. Currently, 8 gurus hold positions in XLV, with a net positive trend of 5 additions versus 3 trims in recent quarters. This indicates growing confidence among top-tier institutional investors in the ETF’s prospects. Insider activity, however, shows no reported purchases or sales in the last 3 to 12 months, suggesting no significant insider trading influence on the ETF’s price.
What This Means for Investors
For income-focused investors, XLV presents a dividend profile that is both attractive and sustainable, supported by a moderate payout ratio and consistent dividend growth. The slight premium to GF Value™ is not alarming and is balanced by a strong GF Score™ and positive guru ownership trends, which signal confidence in the healthcare sector’s stability and growth potential. While momentum is currently subdued, the ETF’s solid fundamentals and backing by influential investors make it a noteworthy option for those seeking steady dividend income within a diversified healthcare exposure. For a deeper dive, explore the XLV stock page and consider screening similar dividend ETFs with the GuruFocus Stock Screener.
Frequently Asked Questions
What is XLV's GF Score™?
XLV’s GF Score™ of 82 out of 100 reflects its strong overall financial health, profitability, and growth prospects, although its momentum is relatively weaker compared to other metrics.
Is XLV's dividend safe?
Yes, XLV’s dividend appears safe with a yield of 1.51%, a conservative payout ratio of 37%, and a solid 8.1% dividend growth rate over the past three years, indicating a stable and growing income stream.
What is XLV's P/E ratio compared to historical?
XLV’s trailing twelve months P/E ratio is 26.92x. However, no 5-year median P/E data is available for comparison, so valuation should be considered alongside other factors such as GF Value™ and guru ownership.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
